EVA1A and hepatocellular carcinoma: One study showed that EVA1A can be downregulated by miR-125b in HCC, thereby increasing the sensitivity of HCC to the chemotherapy drug oxaliplatin, which indicates that the decline in EVA1A expression in the development of HCC may be regulated by miRNAs [11].